Summary
The Realheart TAH system (RTS) is the first total artificial heart designed to mimic the structure and function of the human heart. Its unique patented construction of two atria and two ventricles is separated by an atrioventricular plane which contains the valves, enabling to pump blood naturally whilst reducing the risk of blood flow complications. RTS is designed to be efficient (12h battery), silent, lightweight (2.5kg), easy to implant and automatically adapt to different (physiological) activity levels. It consists of two identical artificial heart pumps, a drive line and an intelligent control unit. RTS is connected via a cable through the skin to a controller carried together with two batteries in a belt around the waist. RTS is aimed as a permanent solution for end-stage heart failure patients, but also for patients waiting for a transplant. Realheart will complete GLP animal trial, clinical trial preparatory activities and first-in-man (EFS) trial during the EIC project.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190157517 |
| Start date: | 01-04-2022 |
| End date: | 31-03-2026 |
| Total budget - Public funding: | 38 241 965,75 Euro - 2 500 000,00 Euro |
Cordis data
Original description
The Realheart TAH system (RTS) is the first total artificial heart designed to mimic the structure and function of the human heart. Its unique patented construction of two atria and two ventricles is separated by an atrioventricular plane which contains the valves, enabling to pump blood naturally whilst reducing the risk of blood flow complications. RTS is designed to be efficient (12h battery), silent, lightweight (2.5kg), easy to implant and automatically adapt to different (physiological) activity levels. It consists of two identical artificial heart pumps, a drive line and an intelligent control unit. RTS is connected via a cable through the skin to a controller carried together with two batteries in a belt around the waist. RTS is aimed as a permanent solution for end-stage heart failure patients, but also for patients waiting for a transplant. Realheart will complete GLP animal trial, clinical trial preparatory activities and first-in-man (EFS) trial during the EIC project.Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Search
